Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
DRTX [NASD]
Durata Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.53 Insider Own0.10% Shs Outstand26.64M Perf Week-9.92%
Market Cap355.64M Forward P/E- EPS next Y-1.33 Insider Trans-96.90% Shs Float26.51M Perf Month-21.47%
Income-66.30M PEG- EPS next Q-0.67 Inst Own90.90% Short Float9.39% Perf Quarter-0.60%
Sales- P/S- EPS this Y24.40% Inst Trans1.72% Short Ratio6.47 Perf Half Y18.14%
Book/sh0.73 P/B18.29 EPS next Y46.20% ROA-65.00% Target Price22.63 Perf Year62.21%
Cash/sh1.56 P/C8.55 EPS next 5Y55.30% ROE-150.50% 52W Range7.73 - 18.17 Perf YTD4.38%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-26.53% Beta-
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low72.70% ATR0.72
Employees106 Current Ratio3.50 Sales Q/Q- Oper. Margin- RSI (14)27.89 Volatility4.18% 5.29%
OptionableYes Debt/Eq1.28 EPS Q/Q12.80% Profit Margin- Rel Volume0.45 Prev Close13.70
ShortableYes LT Debt/Eq1.27 EarningsAug 07 Payout- Avg Volume384.97K Price13.35
Recom1.90 SMA20-16.57% SMA50-16.91% SMA2001.12% Volume174,446 Change-2.55%
20-Jun-14Initiated Gabelli & Co Hold
27-May-14Reiterated RBC Capital Mkts Outperform $19 → $23
23-May-14Initiated MLV & Co Buy $21
09-Apr-14Initiated Summer Street Research Buy $22
01-Apr-14Reiterated RBC Capital Mkts Outperform $17 → $19
18-Jul-14 08:00AM  Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM) GlobeNewswire
20-Jun-14 06:04PM  FDA approves Cubist antibiotic for skin infections AP
09:11AM  Coverage initiated on Durata Therapeutics by Gabelli & Co Briefing.com
09:11AM  Coverage initiated on Durata Therapeutics by Gabelli & Co
17-Jun-14 09:00AM  Durata Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
09:00AM  Durata Therapeutics to Present at Upcoming Investor Conferences
07:54AM  Once-Weekly Vancomycin Challengers: Back To Nature 50 Years Later at Forbes
13-Jun-14 01:59PM  Durata Therapeutics CEO buys 3,000 shares at theflyonthewall.com
01:59PM  Durata Therapeutics CEO buys 3,000 shares
01:59PM  Durata Therapeutics CEO buys 3,00 shares at theflyonthewall.com
01:59PM  Durata Therapeutics CEO buys 3,00 shares
10:43AM  3 Reasons Why Shorts Are Moving into Durata Therapeutics at Motley Fool
10:43AM  3 Reasons Why Shorts Are Moving into Durata Therapeutics
04-Jun-14 05:00PM  New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program GlobeNewswire
05:00PM  New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program
02-Jun-14 04:14PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
04:14PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
28-May-14 07:45PM  3 Stocks to Get on Your Watchlist at Motley Fool
27-May-14 03:47PM  Orexigen Will Run: Here's Why at Seeking Alpha -10.89%
03:47PM  Orexigen Will Run: Here's Why
03:30PM  Durata Therapeutics' Skin Drug Gets FDA Nod Zacks
03:30PM  Durata Therapeutics' Skin Drug Gets FDA Nod
02:07PM  Why Durata Therapeutics Inc. Shares Tumbled at Motley Fool
02:07PM  Why Durata Therapeutics Inc. Shares Tumbled
01:27PM  Nasdaq stocks posting largest percentage decreases AP
11:15AM  High option volume stocks: at theflyonthewall.com
10:00AM  Durata Therapeutics falls 12.1% at theflyonthewall.com
09:26AM  Tuesdays Top Health Care Stories: BioCryst, Durata, Bristol-Myers Squibb, and Incyte at Motley Fool
09:14AM  Pilgrim's Pride pursues Hillshire; Pfizer ends pursuit of AstraZeneca; Sony PlayStation heads to China Hot Stock Minute
09:00AM  Durata can carve out lucrative niche with Dalvance, says Janney Capital at theflyonthewall.com
09:00AM  Durata Therapeutics falls 7.6% at theflyonthewall.com
07:58AM  Pilgrim's Pride bids for Hillshire; Pfizer finished with AstraZeneca; Median CEO pay rises above $10M Hot Stock Minute
07:58AM  BREAKING: Durable goods orders; Pilgrim's Pride bids for Hillshire; Pfizer finished with AstraZeneca Hot Stock Minute
26-May-14 08:00AM  Stocks to watch Tuesday: AutoZone, Workday at MarketWatch
23-May-14 04:21PM  Durata Therapeutics confirms FDA approval of Dalvance at theflyonthewall.com +5.50%
04:17PM  FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults GlobeNewswire
04:13PM  [$$] FDA Approves Durata's Dalvance at The Wall Street Journal
03:48PM  FDA approves Dalvance to treat skin infections at theflyonthewall.com
03:24PM  Durata Therapeutics trading halted, pending news at theflyonthewall.com
05:48AM  Durata Therapeutics initiated with a Buy at MLV & Co. at theflyonthewall.com
02:46AM  Coverage initiated on Durata Therapeutics by MLV & Co Briefing.com
21-May-14 05:12PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
16-May-14 01:04PM  DURATA THERAPEUTICS, INC. Financials EDGAR Online Financials
11:08AM  What's Next For Durata? at Seeking Alpha
13-May-14 04:30PM  Durata Therapeutics Presents Six Dalbavancin Posters at the 24th Annual ECCMID Meeting GlobeNewswire
10:43AM  Durata (DRTX) is in Overbought Territory: What's Next? Zacks
12-May-14 11:30AM  Durata Therapeutics management to meet with Summer Street at theflyonthewall.com +9.24%
09-May-14 03:03PM  [$$] Antibiotics Approvals to Surge at Barrons.com
08:37AM  Durata may get Dalvance decision before May 26, says Janney Capital at theflyonthewall.com
08:30AM  Durata Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
01:09AM  Durata Therapeutics' (DRTX) CEO Paul Edick on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
08-May-14 07:48AM  Durata Therapeutics reports Q1 EPS ex-items (81c), consensus (64c) at theflyonthewall.com
07:31AM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
07:07AM  Q1 2014 Durata Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Durata Therapeutics Reports First Quarter 2014 Financial Results GlobeNewswire
05-May-14 11:56AM  Durata Therapeutics: Approval Probability And Investment Strategy For Dalbavancin at Seeking Alpha +5.78%
02-May-14 08:30AM  Durata Therapeutics to Present Six Dalbavancin Posters at the 24th Annual ECCMID Meeting GlobeNewswire
01-May-14 08:30AM  Durata Therapeutics to Announce First Quarter 2014 Financial Results on May 8, 2014 GlobeNewswire
25-Apr-14 10:34AM  Huge Opportunities Are Now Possible Due To Market Inefficiencies In Valuing Antibiotic Companies Such As Cubist, Durata, And Cellceutix at Seeking Alpha
24-Apr-14 08:30AM  Durata Therapeutics Initiates Enrollment in a Phase 3b Study of Dalvance(TM) in a 1500 mg Single Dose GlobeNewswire
09-Apr-14 09:14AM  Coverage initiated on Durata Therapeutics by Summer Street Research Briefing.com
08-Apr-14 09:32AM  Pfizer Blockbuster Zyvox Under Attack at Motley Fool
07-Apr-14 12:00PM  Over 91% Chance Of Approval For MannKind And Durata Therapeutics at Seeking Alpha
04-Apr-14 06:32PM  What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.? at Motley Fool -5.98%
02-Apr-14 09:05AM  Durata Therapeutics: Gains Ahead at Seeking Alpha
01:54AM  Durata Therapeutics (DRTX) in Focus: Stock Up 5.64% Zacks
31-Mar-14 07:09PM  On The Fly: After Hours Movers at theflyonthewall.com
05:43PM  The Medicines Co. shares lower after rival bacteria drugs gain FDA traction at theflyonthewall.com
05:09PM  FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) GlobeNewswire
04:59PM  After-hours buzz: GM, Humana, Medivation & more at CNBC
04:09PM  Durata's anti-infective drug shows efficacy, safety -FDA panel Reuters
02:52AM  [$$] ING Aims to Resume Dividends at The Wall Street Journal
02:11AM  [$$] ING Aims to Resume Dividends Next Year at The Wall Street Journal
12:12AM  [$$] China Starts Deepwater Gas Production at The Wall Street Journal
20-Mar-14 06:05PM  Nasdaq stocks posting largest percentage decreases AP -6.97%
09:31AM  Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc. at Motley Fool
19-Mar-14 01:04PM  DURATA THERAPEUTICS, INC. Financials EDGAR Online Financials +13.57%
09:45AM  3 Biotechs With Major Catalysts Incoming at Motley Fool
02:32AM  Durata Therapeutics, Inc. (DRTX) in Focus: Stock Up 5.4% Zacks
14-Mar-14 02:29PM  Durata Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
02:29PM  Durata Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript
11:56AM  [$$] Picks to Play the New Antibiotics Bill at Barrons.com
11:56AM  [$$] Picks to Play the New Antibiotics Bill
07:32AM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
07:07AM  Q4 2013 Durata Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results GlobeNewswire
07-Mar-14 08:00AM  Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14, 2014 GlobeNewswire
03-Mar-14 08:00AM  Durata Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
19-Feb-14 02:24AM  Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5% Zacks
02:24AM  Durata Therapeutics (DRTX) Jumps: Stock Rises 6.5%
18-Feb-14 08:00AM  Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare Conference GlobeNewswire +6.50%
14-Feb-14 12:17PM  3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata at Motley Fool
12:17PM  3 Companies Facing FDA Approval: Chelsea, MannKind, and Durata
13-Feb-14 11:22AM  Durata Therapeutics: Primed For Big Gains With March Advisory Committee Date Announced at Seeking Alpha
11:22AM  Durata Therapeutics: Primed For Big Gains With March Advisory Committee Date Announced
08:30AM  Antibiotic Companies To Cash In On In 2014 at Seeking Alpha
08:30AM  Antibiotic Companies To Cash In On In 2014
27-Dec-13 06:00PM  Durata Progresses with Dalbavancin Zacks
06:00PM  Durata Progresses with Dalbavancin
23-Dec-13 08:00AM  European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin GlobeNewswire +5.72%
Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase 3 clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Edick Paul RChief Executive OfficerJun 12Buy15.233,00045,69045,636Jun 13 01:53 PM
DE SCHUTTER RICHARD UDirectorMay 12Buy15.5715,000233,50515,000May 14 05:53 PM
AISLING CAPITAL III LP10% OwnerMar 21Sale15.572,64941,2553,030,175Mar 21 08:08 PM
AISLING CAPITAL III LP10% OwnerMar 20Sale15.7498,0001,542,5893,032,824Mar 21 08:08 PM